The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells

Dynamic expression pattern of Pde4d and its relationship with CpG methylation in the promoter during mouse embryo development

(2013) Zhijun Huang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers

(2013) D.-C. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type 10 Soluble Adenylyl Cyclase Is Overexpressed in Prostate Carcinoma and Controls Proliferation of Prostate Cancer Cells

(2012) Jan-Paul Flacke et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome

(2012) Anna Terrin et al.   JOURNAL OF CELL BIOLOGY

Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation

(2011) Kirsty F. MacKenzie et al.   BIOCHEMICAL JOURNAL

The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study

(2011) Christina G Jespersen et al.   BMC CANCER

Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function

(2011) H. Murdoch et al.   JOURNAL OF CELL SCIENCE

Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions

(2011) Sharron H. Francis et al.   PHYSIOLOGICAL REVIEWS

Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor

(2010) Dennis Merkle et al.   CELLULAR SIGNALLING

Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

(2010) B. Wegiel et al.   CURRENT CANCER DRUG TARGETS

Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs

(2010) Therese Keravis et al.   CURRENT PHARMACEUTICAL DESIGN

Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability

(2010) Sarah N. Rampersad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies

(2010) Ruth Foley et al.   PROSTATE

The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release

(2009) WK Ong et al.   BRITISH JOURNAL OF PHARMACOLOGY

Identification of PDE4D as a Proliferation Promoting Factor in Prostate Cancer Using a Sleeping Beauty Transposon-Based Somatic Mutagenesis Screen

(2009) E. P. Rahrmann et al.   CANCER RESEARCH

Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A

(2009) Andreas Desiniotis et al.   INTERNATIONAL JOURNAL OF CANCER

Neuroendocrine differentiation in the progression of prostate cancer

(2009) Akira Komiya et al.   INTERNATIONAL JOURNAL OF UROLOGY

A luminal epithelial stem cell that is a cell of origin for prostate cancer

(2009) Xi Wang et al.   NATURE

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown

(2009) Miles D. Houslay   TRENDS IN BIOCHEMICAL SCIENCES